AZN
AstraZeneca$68.73
AZN info-0.29%ย โ€ข 24 H
Dividend Yield:2.1%
Global Rank#47
Market Cap$212.79B
YTD Performance2.83%
P/E65.15
Revenue$44.35B
Change 7d1.69%
SP500 BenchmarkUnderperform
P/S4.80
Earnings$3.29B

AstraZeneca (AZN) Stock Overview

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZN Stock Information

SymbolAZN
Address
1 Francis Crick AvenueCambridge, CB2 0AAUnited Kingdom
Founded-
Trading hours9:30 AM - 4:00 PM ET
Websitehttps://www.astrazeneca.com
Country๐Ÿ‡ฌ๐Ÿ‡ง United Kingdom
Phone Number44 20 3749 5000

AstraZeneca (AZN) Price Chart

-
Value:-

AstraZeneca Overview: Key Details and Summary

Stock data
2022
Change
Price
$68.73
N/A
Market Cap
$212.79B
N/A
Shares Outstanding
3.10B
9.17%
Employees
83.50K
N/A
Shareholder Equity
37.06B
-5.67%
Valuation
2022
Change
P/E Ratio
65.15
N/A
P/S Ratio
4.80
N/A
P/B Ratio
5.74
N/A
P/FCF
29.40
N/A
Dividends
2022
Change
Dividend Yield
2.05%
N/A
Dividend per share
1.4096
N/A
Dividend Payout Ratio
1.3252
N/A
Growth
2022
Change
ROIC
0.0592
N/A
CAPEX
-809.00M
N/A
Return on Equity
0.0889
N/A
Earnings
2022
Change
Revenue
$44.35B
N/A
Earnings
$3.29B
N/A
Free Cash Flow
$7.24B
N/A
EPS
1.05
N/A
Earnings Yield
0.0153
N/A
Gross Margin
0.7206
N/A
Operating Margin
0.1028
N/A
Net income margin
0.0742
N/A
FCF Margin
0.1632
N/A
Financial Strength
2022
Change
Total Assets
$96.48B
N/A
Total Debt
$29.23B
N/A
Cash on Hand
$6.24B
N/A
Debt to Equity
$1.60
-4.66%
Cash to Debt
0.2136
2.75%
Current Ratio
0.8593
-26.02%
ยฉ 2024 TopStocks.org
Facebook Icon
Twitter Icon
Linkedin Icon